Arcutis Biotherapeutics (ARQT) vs Dyne Therapeutics (DYN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arcutis Biotherapeutics (ARQT) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 17.5% versus a gain of 14.5%. Over five years, ARQT leads with a +8.5% price change compared with +7.3% for DYN. Dyne Therapeutics is the larger company by market cap ($3.07 billion vs $3.04 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | DYN |
|---|---|---|
| Share price | $24.22 | $16.43 |
| Market cap | $3.04B | $3.07B |
| 1-day change | +0.19% | +2.85% |
| YTD return | -16.77% | -18.35% |
| 1-year return | +17.50% | +14.48% |
| 5-year return | +8.48% | +7.33% |
| P/E ratio (TTM) | 110.07 | — |
| Forward P/E | 17.81 | — |
| EPS (TTM) | $0.22 | $-3.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | — |
| Revenue growth (YoY) | +91.34% | — |
| Net income (latest FY) | $-16.14M | $-446.21M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | — |
| Net margin | -4.29% | — |
| 52-week high | $31.77 | $27.31 |
| 52-week low | $19.30 | $13.73 |
| Distance from 52-week high | -23.78% | -39.85% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +52.80% | +119.18% |
| Average volume | 2.22M | 2.78M |
| Shares outstanding | 125.69M | 186.75M |
| Employees | 354 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
ARQT vs DYN FAQ
Which is bigger, Arcutis Biotherapeutics or Dyne Therapeutics?
Dyne Therapeutics (DYN) is larger, with a market capitalization of $3.07B compared with $3.04B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or DYN?
ARQT returned +17.50% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Dyne Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.